Company news
Enliven Therapeutics, Inc. news in 2021
Enliven Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
December 13, 2021
Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
December 12, 2021
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
November 21, 2021
Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia
November 15, 2021
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
November 8, 2021
Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
November 7, 2021
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
November 3, 2021
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
November 3, 2021
Imara to Participate in Upcoming Investor Conferences
September 14, 2021
Imara to Present at Upcoming Investor Conferences
September 2, 2021
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
August 5, 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
August 4, 2021
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
July 29, 2021
Imara Announces Pricing of Public Offering
July 12, 2021
Imara Announces Launch of Proposed Public Offering
July 12, 2021
Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors
June 29, 2021
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
June 16, 2021
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 10, 2021
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 3, 2021
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 10, 2021
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 3, 2021
Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
March 28, 2021
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
March 16, 2021
Imara Reports Full Year 2020 Financial Results and Business Highlights
March 4, 2021
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
February 25, 2021
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
January 19, 2021
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
January 5, 2021